Investor Relations

Assembly Biosciences (Nasdaq: ASMB) is a biopharmaceutical company developing innovative treatments for hepatitis B virus infection (HBV) and C. difficile-associated diarrhea (CDAD). Both programs have breakthrough potential to provide higher cure rates for these debilitating diseases.

Investor Data

Proxy Statement

2014 Proxy Statement

Annual Report

Thumbnail of 2013 Annual Report cover
2013 Annual Report

© 2014 Assembly Biosciences

Back to top